Anti-Mouse CD178 (FasL) – Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse CD178 (FasL) – Purified in vivo PLATINUM™ Functional Grade
Product No.: M350
Clone MFL3 Target CD178 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names FasL, Fas Ligand, FasL, Apo-1 Ligand, CD95 Ligand, TNFSF6 Isotype IgG Applications B , FC , IF , in vivo |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Armenian Hamster Recommended Dilution Buffer Immunogen B6 mouse FasL cDNA-transfected baby hamster kidney (B6 FasL/BHK) cells Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2894120 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this CD178 antibody, clone MFL3, for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? B IF Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone MFL3 recognizes an epitope on mouse FasL.
Background FasL antibody, clone AFS98, recognizes Fas ligand (FasL), also known as CD178, Apo-1 ligand, and CD95 ligand. FasL is a 40 kDa type II integral membrane protein that belongs to the tumor necrosis factor (TNF) superfamily. FasL is expressed by activated T cells and natural killer (NK cells)1-3. Binding of FasL to its receptor Fas (CD95, APO-1) induces apoptotic cell death in Fas-expressing target cells, contributing to anti-viral immunity. FasL also contributes to peripheral tolerance and the downregulation of immune responses through activation-induced autocrine and paracrine T cell death4. FasL is also found in the anterior chamber of the eye and on Sertoli cells in the testis, and is implicated in immune-privilege at these sites5,6. FasL also contributes to CD8 proliferation and neutrophil recruitment7,8. Soluble FasL (26 kDa) can be released following cleavage by metalloproteinases and block FasL-mediated signaling9. Fas/FasL-signaling is involved in the development of many human diseases, including autoimmunity and cancer10. Many human tumors over-express FasL, resulting in tumor infiltrating lymphocyte (TIL) apoptosis and immune evasion, which is associated with poor prognosis11-14. Antigen Distribution FasL is expressed on activated T cells, NK cells, the eye, and testis.
Ligand/Receptor Fas (CD95) PubMed NCBI Gene Bank ID Research Area Apoptosis . Cell Biology . Cell Death . Immunology . Neuroscience . Tumor Suppressors Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone MFL3 is most commonly used for in vivo blockade of Fas Ligand (FasL/CD178) in mice to inhibit FasL-mediated apoptotic signaling and modulate immune responses. Key in vivo applications include:
Other technical applications in vivo:
Summary Table: Common In Vivo Applications of Clone MFL3 in Mice
MFL3 is validated across mouse strains and is formulated for high purity, ultra-low endotoxin, and specific in vivo compatibility to minimize off-target or immunogenic effects in mouse models. Based on research applications, MFL3 is commonly used in combination with several other antibodies and proteins to investigate immune cell function and apoptosis pathways. T Cell Activation StudiesMFL3 is most frequently paired with anti-CD3 antibodies when investigating T cell activation. The anti-CD3 antibody clone 145-2C11 is a well-characterized reagent used to stimulate T cells, and researchers combine it with MFL3 to study the downstream effects of T cell activation on FasL expression and Fas-mediated apoptosis. Apoptosis Pathway ResearchFor studying apoptotic mechanisms, MFL3 is commonly used alongside anti-Fas (CD95) antibodies. Since MFL3 targets the Fas Ligand (CD178), which binds to its receptor CD95/Fas to induce apoptotic cell death, pairing these antibodies allows researchers to comprehensively examine both sides of this critical death receptor-ligand interaction. This combination is particularly valuable for investigating how Fas/FasL interactions participate in T cell development, immune response regulation, and cell-mediated cytotoxic mechanisms. Flow Cytometry ApplicationsIn flow cytometry experiments, MFL3 is paired with a range of fluorescently labeled antibodies for detailed immune cell analysis. The antibody is available conjugated to various fluorophores including PE, APC-eFluor, and FITC, making it compatible with multi-color flow cytometry panels that include markers for different T cell subsets, activation markers, and other immune cell populations. The key findings from scientific literature citing clone MFL3 focus on its specificity and functional use in mouse immunology research:
These findings make MFL3 an essential tool in studies exploring murine FasL biology, apoptosis, and immune modulation, with broad applications across immunology and related biomedical research. Dosing Regimens of Clone MFL3 (Anti-Mouse Fas Ligand/CD178) Across Mouse ModelsClone MFL3 is a monoclonal antibody that targets mouse Fas ligand (FasL, CD178), a protein involved in apoptosis and immune regulation. While its biological effects—such as blocking apoptosis—have been demonstrated in specific experiments, the dosing regimens for MFL3 are not standardized across different mouse models and research applications. General Considerations
Published Example
Best Practices for Determining MFL3 Dosing
SummaryThere is no uniform dosing regimen for clone MFL3 across different mouse models due to insufficient published data and vendor guidance. Researchers should design model-specific pilot experiments to determine optimal MFL3 doses and schedules, drawing on general principles for monoclonal antibody administration in mice when necessary. Always consult the primary literature and consider collaboration with laboratories that have previously used MFL3 in similar contexts for protocol refinement. References & Citations1. Okumura K., et al. (1994) Proc Natl Acad Sci USA. 91:4930–4934 2. Nagata S., et al. (1995) J Immunol. 154:3806–3813 3. Saito T., et al. (1995) J Exp Med. 181:1235–1238 4. Ferguson T A., et al. (1995) Science. 270:1189–1192 5. Duke R C., et al. (1995) Nature (London). 377:630–632 6. Fink PJ. (2000) J Immunol. 165(10):5537-43 7. Matsuzawa A., et al. (1998) J Immunol. 161: 4484–4488 8. Nagata S., et al. (1998) Nat Med. 4(1):31-6 9. Hueber AO., et al (2019) Cancers (Basel). 11(5):639 10. Kabelitz D., et al. (2000) Cancer Res. 60: 822–828 11. Giannarelli D., et al. (2000) Int J Cancer. 89: 127–132 12. Kanno H., et al. (2000) Br J Cancer. 82: 1446–1452. 13. Nagano H., et al. (Cancer) Br J Cancer. 82: 1211–1217 Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
M351 | |
M354 | |
M353 | |
M352 | |
M355 | |
M350 |
